Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 425 • 2013 ACR/ARHP Annual Meeting
Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial
Gerd Burmester¹, Alan J. Kivitz², Hartmut Kupper³, Udayasankar Arulmani⁴, Stefan Florentinus⁵, Sandra Goss⁴, Suchitrita S. Rathmann⁴ and Roy Fleischmann⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, Rungis, France, ⁶University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Anti-TNF plus methotrexate (MTX) is more effective than either as monotherapy. Thus far, no controlled data are available on the benefit:risk of different doses…
Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…
Abstract Number: 437 • 2013 ACR/ARHP Annual Meeting
Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang¹, Lang Chen³, Huifeng Yun⁴, Michael H. Schiff⁵, David Mackey⁶ and Seth Ginsberg⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Division, University of Colorado, Denver, CO, ⁶Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Creaky Joints, New York, NY
Background/Purpose: Although methotrexate (MTX) is the cornerstone of RA treatment, use of oral and subcutaneous (SC) preparations in real-world settings is not well characterized. Methods:…
Abstract Number: 2339 • 2013 ACR/ARHP Annual Meeting
Patient Evaluations Of Subcutaneous Golimumab Delivery By Autoinjector (SmartJect®) For Treatment Of Rheumatoid Arthritis
H Schulze-Koops¹, R Giacomelli², W Samborski³, S Rednic⁴, M Herold⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹University of Munich, Munich, Germany, ²Università degli Studi dell'Aquila, L'Aquila, Italy, ³Ortopedyczno-Rehabilitacyjny Szpital Kliniczny, Wielkopolskie, Poland, ⁴University of Medicine & Pharmacy, Cluj-Napoca, Romania, ⁵Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Self-injection of subcutaneous (SC) golimumab (GLM) using an autoinjector device may be useful for patients with rheumatoid arthritis (RA), especially if they have functional…
Abstract Number: L3 • 2013 ACR/ARHP Annual Meeting
A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
MC Genovese¹, Ronald van Vollenhoven², Bradley J. Bloom³, John G. Jiang³ and Nils Kinnman⁴, ¹Stanford University, Palo Alto, CA, ²Karolinska Institute, Stockholm, Sweden, ³Vertex Pharmaceuticals Incorporated, Cambridge, MA, ⁴Vertex Pharmaceuticals Incorporated, Eysins, Switzerland
Background/Purpose: VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). The objective of this 24-week, randomized, placebo-controlled, double-blind,…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 1954 • 2013 ACR/ARHP Annual Meeting
advantages Of a Combined Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) For Hand and Feet: Does The Ramris Of The Hand Alone Underestimate Disease Activity and Progression?
Dr. Philipp Sewerin¹, Dr. Christian Buchbender², Dr. Stefan Vordenbäumen¹, Dr. Axel Scherer², Dr. Falk Miese², Dr. Ralph Brinks³, Dr. Hans-Jörg Wittsack⁴, Prof. Dr. Gerald Antoch⁴, Prof. Dr. Matthias Schneider³ and Prof. Dr. Benedikt Ostendorf¹, ¹Department of Rheumatology, Univ. Duesseldorf, Düsseldorf, Germany, ²Department of Diagnostic and Interventional Radiology, Univ. Duesseldorf, Düsseldorf, Germany, ³Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ⁴Department Diagnostic and Interventional Radiology, Univ. Duesseldorf, Düsseldorf, Germany
Background/Purpose: To evaluate a combined rheumatoid arthritis magnetic resonance imaging score (RAMRIS) for hand and foot (HaF-score) in rheumatoid arthritis (RA). Methods: Magnetic resonance imaging…
Abstract Number: 1872 • 2013 ACR/ARHP Annual Meeting
Gene-Body Mass Index Interactions Are Associated With Methotrexate Toxicity in Rheumatoid Arthritis
Stella Aslibekyan¹, Jin Sha¹, David T. Redden², Larry W. Moreland³, James R. O'Dell⁴, Jeffrey R. Curtis⁵, Ted R. Mikuls⁶, S. Louis Bridges Jr.⁷ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Response to methotrexate (MTX) therapy in rheumatoid arthritis (RA) is highly heterogeneous, with both genetic and environmental factors contributing to the efficacy and toxicity…
Abstract Number: 1796 • 2013 ACR/ARHP Annual Meeting
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Yoshiya Tanaka¹, Kahaku Emoto², Mika Tsujimoto², Douglas E. Schlichting³ and William Macias³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Eli Lilly Japan K.K., Kobe, Japan, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 12-week blinded phase…
Abstract Number: 1467 • 2013 ACR/ARHP Annual Meeting
Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study
Ghada Ahmed¹, Sandra L Goss¹, Cheri E Klein¹, Neelufar Mozaffarian², Gurjit S. Kaeley³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²Eli Lilly, San Diego, CA, ³College of Medicine, University of Florida, Jacksonville, FL
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) may be initiated on combination therapy with anti-TNF agents such as adalimumab. However, it…
Abstract Number: 1445 • 2013 ACR/ARHP Annual Meeting
GEMS Audit: An Evaluation Of Routine Use Of Subcutaneous Methotrexate In Rheumatoid Arthritis
Esme Roads¹, Scot Buchan² and Charles Li³, ¹Royal Surrey County Hospital, Guildford, United Kingdom, ²Strategen Ltd, Basingstoke, United Kingdom, ³Rheumatology, Royal Surrey County Hospital, Guildford, United Kingdom
Background/Purpose: Methotrexate (MTX) forms the backbone of treatment for the majority of patients with rheumatoid arthritis (RA), and is advocated in most guidelines.[i],[ii],[iii] Existing studies imply…
Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Kim Hørslev-Petersen¹, Lykke Midtbøll Ørnbjerg², Merete Lund Hetland³, Peter Junker⁴, Jan Pødenphant⁵, Torkell Ellingsen⁶, Palle Ahlqvist⁷, Hanne M. Lindegaard⁸, Asta Linauskas⁹, Annette Schlemmer¹⁰, Mette Y. Dam¹¹, Ib Hansen¹², Tine Lottenburger⁷, Anette Jørgensen¹³, Sophine B. Krintel¹⁴, Johnny Raun¹⁵, Christian G. Ammitzbøll¹¹, Julia Johansen¹⁴, Mikkel Østergaard¹⁶ and Kristian Stengaard-Pedersen¹¹, ¹Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ²Copenhagen Center for Arthritis Reasearch, Center for Rheumatology and Spine diseases, Glostrup Hospital, Copenhagen, Denmark, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴University of Southern Denmark, Odense, Denmark, ⁵Copenhagen University at Gentofte, Hellerup, Denmark, ⁶Silkeborg Regional Hospital, Silkeborg, Denmark, ⁷University of Southern Denmark, Vejle, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Vendsyssel Hospital, Hjørring, Denmark, ¹⁰Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹¹Arhus University Hospital, Aarhus, Denmark, ¹²Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹³Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹⁴Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ¹⁵University of Southern Denmark, Graasten, Denmark, ¹⁶Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…
Abstract Number: 1409 • 2013 ACR/ARHP Annual Meeting
Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial
Edward C. Keystone¹, Ferdinand C. Breedveld², Désiréé van der Heijde², Robert Landewe³, Stefan Florentinus⁴, Udayasankar Arulmani⁵, Shufang Liu⁵, Hartmut Kupper⁶ and Arthur Kavanaugh⁷, ¹University of Toronto, Toronto, ON, Canada, ²Leiden University Medical Center, Leiden, Netherlands, ³Academic Medical Center, Amsterdam, Netherlands, ⁴AbbVie, Rungis, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷University of California San Diego, San Diego, CA
Background/Purpose: The PREMIER trial demonstrated the superiority of initial adalimumab (ADA)+MTX vs the individual monotherapies in MTX-naïve patients (pts) with early, aggressive rheumatoid arthritis (RA).…
Abstract Number: 1054 • 2013 ACR/ARHP Annual Meeting
Use Of Oral and Subcutaneous MTX In a Commercially Insured Rheumatoid Arthritis Population
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang³, Lang Chen⁴, Huifeng Yun⁵, Michael H. Schiff⁶, Timothy Beukelman⁷ and Seth Ginsberg⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Creaky Joints, New York, NY
Background/Purpose: Methotrexate (MTX) is the most commonly used medication in rheumatoid arthritis (RA), although use of oral and subcutaneous (SQ) preparations in real-world settings has…
Abstract Number: 1037 • 2013 ACR/ARHP Annual Meeting
Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa)
Atsushi Hashimoto¹, Noriyuki Chiba², Jinju Nishino³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ³Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁴Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose :Patients with rheumatoid arthritis (RA) die mainly of cardiovascular/cerebrovascular diseases, respiratory diseases, infections, or malignancies. In recent years, the ratio of infections and respiratory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].